 Enveric Biosciences Inc has announced that EV102, its cannabidiol-based product CBD in development for the topical prescription treatment of radiodermatitis, has demonstrated a significant and meaningful reduction in dermatitis severity, skin redness, and duration in a preclinical rodent model. Cancer patients around the world suffer the harsh side effects of various anti-cancer treatments, said CEO Dr. Joseph Tucker in a statement. 